Welcome to our dedicated page for Atea Pharmaceuticals SEC filings (Ticker: AVIR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Parsing Atea Pharmaceuticals’ dense biotech disclosures can feel like deciphering lab notes written in legalese. Phase 3 trial endpoints, cash-runway projections, and nuanced risk factors are scattered across hundreds of pages—exactly where critical clues hide for COVID-19 and hepatitis C investors.
Stock Titan turns that challenge into clarity. Our platform delivers AI-powered summaries that transform every Atea Pharmaceuticals quarterly earnings report 10-Q filing into an accessible brief, highlight cash-burn trends inside the annual report 10-K simplified, and flag material trial results through Atea Pharmaceuticals 8-K material events explained. Need to track executive sentiment? Receive real-time alerts on Atea Pharmaceuticals Form 4 insider transactions — the same data many professionals watch minutes after it posts to EDGAR.
Whether you’re screening Atea Pharmaceuticals insider trading Form 4 transactions for buying patterns, comparing pipeline updates across filings, or simply understanding Atea Pharmaceuticals SEC documents with AI, our coverage is complete. You’ll find:
- Instant, searchable access to every 10-K, 10-Q, 8-K, S-1, and DEF 14A proxy statement executive compensation disclosure
- AI commentary that links trial milestones to revenue projections for swift Atea Pharmaceuticals earnings report filing analysis
- Push notifications for Atea Pharmaceuticals executive stock transactions Form 4 in real time
Save hours combing through technical appendices. With Stock Titan, Atea Pharmaceuticals SEC filings explained simply are just a click away, giving you the insight to act before the market does.
ServiceTitan, Inc. (SEC File No. 001-42434) has received a Form 144 notice covering a proposed sale of 66,625 Class A common shares by Bessemer Venture Partners VIII Institutional L.P., a 10 % stockholder. The shares are to be sold through Merrill Lynch, Pierce, Fenner & Smith Inc. on or about 26 June 2025 on the NASDAQ exchange. The filing assigns an aggregate market value of $6.94 million to the planned trade, based on the price prevailing when the form was prepared.
The notice also discloses substantial recent activity by Bessemer-affiliated funds and related entity 15 Angels II LLC. Over the past three months, these sellers have disposed of 512,543 Class A shares in multiple transactions—221,596 and 266,502 shares on 10 June 2025, and smaller blocks on 25 June 2025—generating approximately $52.3 million in gross proceeds. Adding the newly filed 66,625-share block lifts cumulative disclosed sales to 579,168 shares, or about 0.75 % of the 77.27 million shares outstanding.
The filing states that the seller "does not know any material adverse information" not already public and affirms compliance with Rule 144 resale conditions. No purchase-price contingencies are noted; the securities were originally acquired via a private cash purchase on 20 March 2015.
Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) filed an 8-K summarising the results of its 20 June 2025 Annual Meeting of Stockholders.
- Quorum: 74,981,407 shares (≈87.6 % of outstanding) were represented in person or by proxy.
- Director elections (Class II, terms expiring 2028):
- Bruno Lucidi - 46,640,587 FOR / 12,559,084 WITHHOLD / 15,781,736 broker non-votes.
- Polly Murphy, DVM, PhD - 41,184,263 FOR / 18,015,408 WITHHOLD / 15,781,736 broker non-votes.
- Bruce Polsky, MD - 46,597,653 FOR / 12,602,018 WITHHOLD / 15,781,736 broker non-votes.
- Auditor ratification: KPMG LLP re-appointed for FY 2025 with 73,766,274 FOR, 1,192,659 AGAINST, 22,474 ABSTAIN; no broker non-votes.
- Say-on-pay (advisory): 46,450,302 FOR, 12,107,029 AGAINST, 642,340 ABSTAIN, 15,781,736 broker non-votes.
All three proposals passed. No other material business was disclosed in the filing.
FAQ
What is the current stock price of Atea Pharmaceuticals (AVIR)?
What is the market cap of Atea Pharmaceuticals (AVIR)?
What is Atea Pharmaceuticals’ core focus?
What makes Atea’s approach to antiviral therapy unique?
Which viral infections are addressed by Atea’s product candidates?
At what stage are Atea’s clinical trials?
How does Atea’s scientific expertise enhance its drug development?
What differentiates Atea’s HCV treatment approach?
How does Atea ensure its information remains evergreen?
What are the key areas of expertise that drive Atea’s innovation?
